Lasa Supergenerics Past Earnings Performance
Past criteria checks 0/6
Lasa Supergenerics's earnings have been declining at an average annual rate of -46.3%, while the Pharmaceuticals industry saw earnings growing at 15.2% annually. Revenues have been declining at an average rate of 11.2% per year.
Key information
-46.3%
Earnings growth rate
-35.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -11.2% |
| Return on equity | -20.2% |
| Net Margin | -18.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
There's No Escaping Lasa Supergenerics Limited's (NSE:LASA) Muted Revenues
Aug 08
We Think Lasa Supergenerics (NSE:LASA) Has A Fair Chunk Of Debt
Jun 05Little Excitement Around Lasa Supergenerics Limited's (NSE:LASA) Revenues As Shares Take 26% Pounding
Mar 13Improved Revenues Required Before Lasa Supergenerics Limited (NSE:LASA) Stock's 25% Jump Looks Justified
Dec 28We Think Lasa Supergenerics (NSE:LASA) Has A Fair Chunk Of Debt
Jul 05Lasa Supergenerics (NSE:LASA) Is Carrying A Fair Bit Of Debt
Mar 28Lasa Supergenerics' (NSE:LASA) Dividend Will Be ₹0.25
Sep 02Would Lasa Supergenerics (NSE:LASA) Be Better Off With Less Debt?
Aug 13A Look At The Fair Value Of Lasa Supergenerics Limited (NSE:LASA)
Jun 21Is Lasa Supergenerics (NSE:LASA) Using Too Much Debt?
Dec 06Revenue & Expenses Breakdown
How Lasa Supergenerics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,046 | -195 | 63 | 0 |
| 31 Mar 24 | 1,043 | -217 | 63 | 0 |
| 31 Dec 23 | 1,168 | -214 | 69 | 0 |
| 30 Sep 23 | 1,219 | -249 | 50 | 0 |
| 30 Jun 23 | 1,312 | -315 | 59 | 0 |
| 31 Mar 23 | 1,296 | -386 | 80 | 0 |
| 31 Dec 22 | 1,455 | -113 | 101 | 0 |
| 30 Sep 22 | 1,295 | -111 | 88 | 0 |
| 30 Jun 22 | 1,299 | -183 | 92 | 0 |
| 31 Mar 22 | 1,371 | -53 | 74 | 0 |
| 31 Dec 21 | 1,250 | -139 | 135 | 0 |
| 30 Sep 21 | 1,633 | -26 | 158 | 0 |
| 30 Jun 21 | 1,838 | 182 | 149 | 0 |
| 31 Mar 21 | 2,024 | 228 | 145 | 0 |
| 31 Dec 20 | 2,118 | 216 | 148 | 0 |
| 30 Sep 20 | 1,972 | 176 | 140 | 0 |
| 30 Jun 20 | 1,829 | 101 | 134 | 0 |
| 31 Mar 20 | 1,673 | 36 | 142 | 0 |
| 31 Dec 19 | 1,607 | -8 | 139 | 0 |
| 30 Sep 19 | 1,753 | -86 | 134 | 0 |
| 30 Jun 19 | 1,756 | -101 | 120 | 0 |
| 31 Mar 19 | 1,696 | -120 | 125 | 0 |
| 31 Dec 18 | 1,869 | -167 | 120 | 0 |
| 30 Sep 18 | 1,940 | -83 | 116 | 0 |
| 30 Jun 18 | 2,175 | 55 | 115 | 0 |
| 31 Mar 18 | 2,435 | 123 | 110 | 0 |
| 30 Jun 17 | 2,184 | -10 | 102 | 0 |
| 31 Mar 17 | 2,182 | 24 | 98 | 0 |
Quality Earnings: LASA is currently unprofitable.
Growing Profit Margin: LASA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LASA is unprofitable, and losses have increased over the past 5 years at a rate of 46.3% per year.
Accelerating Growth: Unable to compare LASA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LASA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.3%).
Return on Equity
High ROE: LASA has a negative Return on Equity (-20.18%), as it is currently unprofitable.